Home > Products > HS-388 011

Histone3.3 G34V antibody - HS-388 011 K.O.

Histone 3.3 G34V is a driver mutation in paediatric glioblastoma
Mouse monoclonal purified IgG
Cat. No.: HS-388 011
Amount: 100 µg
Price: $415.00
Cat. No. HS-388 011 100 µg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: not recommended
IP: not tested yet
ICC: not tested yet
IHC: not tested yet
IHC-P: 1 : 1000 up to 1 : 2000 gallery  
ChIP: yes

Western blot (WB); separation of proteins by PAGE and subsequent transfer to a membrane. Detection of target molecules is carried out with antibodies. Some antibodies require special sample preparation steps. For details, please refer to the “Remarks” section.

Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section.

Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.

Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.

Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.

Chromatin Immunoprecipitation is employed to isolate protein DNA complexes in order to determine protein binding sites on DNA.
Clone 329E5
Subtype IgG2b
Immunogen Synthetic peptide corresponding to AA 29 to 38 from human H3F3A G34V (UniProt Id: P84243)
Reactivity Reacts with: human (P84243).
Other species not tested yet.
Specificity Specific for the H3.3 G34V mutant. Negligible cross-reactivity to H3.3 G34R, and no cross-reactivity to unmutated H3.3. K.O. validated
Data sheet hs-388_011.pdf

References for Histone3.3 G34V - HS-388 011

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.
Liu I, Alencastro Veiga Cruzeiro G, Bjerke L, Rogers RF, Grabovska Y, Beck A, Mackay A, Barron T, Hack OA, Quezada MA, Molinari V, et al.
Cancer cell (2024) : . HS-388 011 ICC, WB; tested species: human
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.
Liu I, Alencastro Veiga Cruzeiro G, Bjerke L, Rogers RF, Grabovska Y, Beck A, Mackay A, Barron T, Hack OA, Quezada MA, Molinari V, et al.
Cancer cell (2024) : . HS-388 011 ICC, WB; tested species: human
Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F, Antonelli M, Di Dio T, Minasi S, Donofrio V, Buccoliero AM, Gardiman MP, Pollo B, Diomedi Camassei F, Rossi S, Novello M, et al.
The American journal of surgical pathology (2021) 452: 200-204. HS-388 011 IHC-P; tested species: human
Cat. No.: HS-388 011
Amount: 100 µg
Price: $415.00

H3.3 G34V mutation detection in xenograft model of pedriatic high-grade glioma

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.
Liu I, Alencastro Veiga Cruzeiro G, Bjerke L, Rogers RF, Grabovska Y, Beck A, Mackay A, Barron T, Hack OA, Quezada MA, Molinari V, et al.
Cancer cell (2024) : . HS-388 011 ICC, WB; tested species: human
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant.
Liu I, Alencastro Veiga Cruzeiro G, Bjerke L, Rogers RF, Grabovska Y, Beck A, Mackay A, Barron T, Hack OA, Quezada MA, Molinari V, et al.
Cancer cell (2024) : . HS-388 011 ICC, WB; tested species: human
Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F, Antonelli M, Di Dio T, Minasi S, Donofrio V, Buccoliero AM, Gardiman MP, Pollo B, Diomedi Camassei F, Rossi S, Novello M, et al.
The American journal of surgical pathology (2021) 452: 200-204. HS-388 011 IHC-P; tested species: human
IHC-P
IHC-P
Background
The gene mutations H3.3 G34V and H3.3 G34R of histone 3.3 (H3.3 or H3F3A) have been recently identified as driver mutations in paediatric glioblastoma. G34V/R mutations are restricted to tumors of the cerebral hemispheres and are most prevalent in adolescents and young adults. These mutations cause profound upregulation of MYCN, a potent oncogene. Emerging evidence strongly suggests that paediatric glioblastomas with H3F3A mutations can be subclassified into distinct entities.

This antibody is part of the HistoSure® product line, specifically developed and tested for human pathology.